TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
NVO

Novo Nordisk A/S

Healthcare · Drug Manufacturers - General

40.70$ -1.1% vs. previous close Closing price · As of: Nov 12, 2026

Statements

Balance Sheet

Novo Nordisk A/S (NVO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 542,902 million DKK. Tick rows to compare them in a chart.

All figures in millions of DKK.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NVO
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
77,062 91,799 97,539 102,355 110,769 125,612 144,922 194,508 241,257 314,486 465,795 542,902
46,293 55,140 59,766 60,080 59,067 62,456 65,809 85,595 108,194 139,646 160,897 172,453
14,396 16,923 18,690 18,852 15,638 15,475 12,757 10,720 12,653 14,392 15,655 26,464
15,905 20,465 20,699 18,852 15,638 15,475 12,757 17,485 23,574 30,230 26,308 26,962
15,791 17,742 24,197 23,551 26,889 29,152 32,184 46,799 57,505 75,261 87,414 75,697
11,357 12,758 14,341 15,373 16,336 17,641 18,536 19,621 24,388 31,811 40,849 49,623
3,760 25,545 30,179 35,247 41,891 50,551 50,269 55,362 66,671 90,961 162,488 208,378
– 0.0 0.0 0.0 0.0 0.0 0.0 4,346 5,092 4,464 20,064 19,845
1,378 2,158 2,714 3,325 5,145 5,835 20,657 38,825 46,324 55,942 91,026 110,208
36,768 44,830 52,270 52,540 58,930 68,019 81,597 123,762 157,771 207,925 322,309 348,855
33,689 40,873 47,436 47,056 54,164 58,983 70,273 99,516 120,940 169,655 217,528 215,661
720 1,073 229 1,694 515 1,474 7,459 13,684 1,466 6,478 13,113 12,017
4,950 4,927 6,011 5,610 6,756 6,358 5,717 8,870 15,587 25,606 28,846 19,758
– 0.0 0.0 0.0 0.0 0.0 – 9,654 20,775 15,976 84,246 118,941
40,294 46,969 45,269 49,815 51,839 57,593 63,325 70,746 83,486 106,561 143,486 194,047
41,277 46,816 46,111 48,977 53,406 57,817 63,774 72,004 80,587 104,839 144,448 195,298
5,260 5,157 5,070 4,956 4,849 4,757 4,680 4,606 4,545 4,495 4,463 4,448

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?